- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07648420
Using Apollo Neuro in Autistic Children With Self-Injurious Behavior
Feasibility and Usability of the Apollo Neuro, a Wearable Sensory Device, in Autistic Children With Self-Injurious Behavior
This study will evaluate the feasibility and acceptability of the Apollo Neuro, a wearable vibrotactile sensory device, in autistic children who engage in self-injurious behavior (SIB).
Participants will wear the device for at least 3 hours per day over a 30-35 day period with caregiver support. Outcomes will include adherence to device use, caregiver-reported feasibility and acceptability, and descriptive characterization of caregiver-reported self- injurious and repetitive behaviors during the study period. This preliminary, single-group study is not designed to evaluate efficacy and will inform the design of future controlled trials.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Laura Lee Robins
- Номер телефона: (757) 285-3486
- Электронная почта: robinslp@vcu.edu
Места учебы
-
-
Virginia
-
Richmond, Virginia, Соединенные Штаты, 23298
- Virginia Commonwealth Uniersity
-
Контакт:
- Laura Robins
- Номер телефона: 757-541-8460
- Электронная почта: robinslp@vcu.edu
-
Главный следователь:
- Stacey Reynolds
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
Принимает здоровых добровольцев
Описание
Inclusion Criteria for child:
- Diagnosis of autism spectrum disorder (ASD), as reported by caregiver
- Presence of self-injurious behavior, as reported by caregiver
- Demonstrates sensory over and/or under- responsivity
- Aged 6 years to 14 years, 11 months (179 months) at the time of enrollment
- Has a caregiver willing and able to provide consent and participate in study procedures
Exclusion Criteria for child:
Has medical condition that may increase risk with use of a wearable nibrotactile device, including:
- implanted medical or neurological devices (e.g., pacemaker)
- significant cardiac conditions or arrhythmias
- history of syncope (fainting)
- Known seizure disorder without physician clearance
- Regular use of nibrotactile or autonomic- modulating wearable devices within the past 90 days
- Any condition that, in the judgment of the investigator, would interfere with safe participation or interpretation of study procedures
Inclusion Criteria for Caregiver:
- Parent or legal guardian of the enrolled child participant
- Able to provide informed consent in English
- Able and willing to support device use according to study protocol and complete study-related data collection
- Has access to a smartphone or compatible device capable of operating the Apollo Neuro application for the duration of study period
Exclusion Criteria for Caregiver:
• Unable to provide informed consent in English
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Apollo Neuro device
Wearing of activated Apollo Neuro device for at least three hours/day for 30 of 35 consecutive days by Autistic children with SIB and sensory over and/or under responsivity.
|
Child participants will wear the activated device for a minimum of three hours per day on at least 30 of 35 consecutive days, consistent with the study protocol.
The device is worn externally (e.g., wrist, ankle, or waist) and delivers low intensity vibrations through intact skin.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Adherence to wearing the Apollo Neuro Wearable
Временное ограничение: 30-35 days
|
Caregiver-reported acceptability of the intervention, as measured by the Acceptability of Intervention Measure (AIM), a validated 4-item instrument assessing the perceived agreeableness, satisfaction, and usability of the intervention.
Each item is rated on a 5-point Likert scale ranging from 1 (Completely disagree) to 5 (Completely agree).
Responses will be summarized descriptively using mean scores and response distributions.
|
30-35 days
|
|
Acceptability of Intervention Measure (AIM)
Временное ограничение: 30-35 days
|
Caregiver-reported acceptability of the intervention, as measured by the Acceptability of Intervention Measure (AIM), a validated 4-item instrument assessing the perceived agreeableness, satisfaction, and usability of the intervention.
Each item is rated on a 5-point Likert scale ranging from 1 (Completely disagree) to 5 (Completely agree).
Responses will be summarized descriptively using mean scores and response distributions.
|
30-35 days
|
|
The Repetitive Behavior Scale-Revised (RBS-R)
Временное ограничение: 30-35 days
|
Caregiver-reported behaviors, as measured by the Repetitive Behavior Scale-Revised (RBS-R), a validated 43-item questionnaire assessing the presence and severity of restricted and repetitive behaviors in individuals with autism spectrum disorder, including self-injurious behavior.
The measure is completed by caregivers at baseline and post-intervention using a 4-point Likert scale.
Scores will be summarized descriptively to characterize patterns over the study period.
|
30-35 days
|
|
Changes in caregiver-reported SIB intensity
Временное ограничение: 30-35 days
|
Daily caregiver-reported ratings of peak self-injurious behavior intensity, measured using a visual analog scale (VAS) recorded on a study-designed data collection form.
Caregivers will provide ratings each day throughout the intervention period.
Data will be summarized descriptively to characterize variability and patterns over time.
|
30-35 days
|
|
Feasibility of Intervention Measure (FIM)
Временное ограничение: 30-35 days
|
Caregiver-reported feasibility of the intervention, as measured by the Feasibility of Intervention Measure (FIM), a validated 4-item instrument assessing the extent to which the intervention can be successfully implemented within the home setting.
Each item is rated on a 5-point Likert scale ranging from 1(Completely disagree) to 5 (Completely agree).
Responses will be summarized descriptively using mean scores and response distributions.
|
30-35 days
|
|
Change in intensity of self-injurious behavior
Временное ограничение: 30-35 days
|
Changes in the intensity of self-injurious behavior associated with the use of the Apollo Neuro wearable device will be measured by caregiver-reported tracking daily ratings of peak self-injurious behavior intensity on a study designed form tracking the participant adherence.
|
30-35 days
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Stacey Reynolds, Virginia Commonwealth University
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- HM300001048
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .